Published in JAMA Intern Med on February 01, 2015
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA (2016) 2.23
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 1.20
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc (2017) 1.06
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. Curr Opin HIV AIDS (2016) 0.98
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf (2015) 0.85
Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2016) 0.83
Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. J Infect Dis (2016) 0.81
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Acquir Immune Defic Syndr (2016) 0.80
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.80
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV (2016) 0.78
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis (2016) 0.76
Preexposure prophylaxis: a path forward. JAMA Intern Med (2015) 0.76
Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate? PLoS One (2016) 0.75
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. J Gen Intern Med (2016) 0.75
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. Infect Dis Ther (2015) 0.75
Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS One (2017) 0.75
Clinical trials. Renal safety of TDF as pre-exposure prophylaxis for HIV-1 infection. Nat Rev Nephrol (2015) 0.75
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Infect Dis Ther (2017) 0.75
Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. AIDS (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest (1950) 9.22
Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc (1985) 7.02
Regression to the mean: what it is and how to deal with it. Int J Epidemiol (2004) 6.29
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int (2011) 5.70
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int (2010) 2.95
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS (2006) 2.28
Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics (1997) 2.21
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr (2010) 1.74
Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int (2010) 1.65
Randomized trials analyzed as observational studies. Ann Intern Med (2013) 1.60
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis (2012) 1.40
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34
Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience. J Acquir Immune Defic Syndr (2014) 1.11
A comparison of cystatin C- and creatinine-based prediction equations for the estimation of glomerular filtration rate in black South Africans. Nephrol Dial Transplant (2010) 1.04
Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. PLoS One (2013) 1.04
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res (2012) 0.97
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis (2014) 2.05
Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA (2014) 1.73
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis (2015) 1.71
Improving facility performance in infectious disease care in Uganda: a mixed design study with pre/post and cluster randomized trial components. PLoS One (2014) 1.49
Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. Lancet Glob Health (2014) 1.49
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med (2014) 1.24
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (2013) 1.19
Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr (2014) 1.09
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 1.02
Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS (2014) 0.97
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 0.97
Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS (2014) 0.96
Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr (2013) 0.94
Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy. J Infect Dis (2016) 0.90
Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. J Infect Dis (2014) 0.83
Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. Am J Epidemiol (2015) 0.82
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV (2017) 0.82
Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. J Infect Dis (2016) 0.81
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.80
Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions. PLoS One (2015) 0.78
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS (2016) 0.78
Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. AIDS Behav (2016) 0.77
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. AIDS (2014) 0.76
Effect of Educational Outreach Timing and Duration on Facility Performance for Infectious Disease Care in Uganda: A Trial with Pre-Post and Cluster Randomized Controlled Components. PLoS One (2015) 0.75
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. J Acquir Immune Defic Syndr (2016) 0.75
Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding. PLoS One (2015) 0.75
Medication Sharing is Rare among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. J Acquir Immune Defic Syndr (2017) 0.75
Effectiveness of educational outreach in infectious diseases management: a cluster randomized trial in Uganda. BMC Public Health (2016) 0.75
Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships. Sex Transm Dis (2017) 0.75
The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion. AIDS (2017) 0.75
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. AIDS (2019) 0.75